SCHEMBL524374

SCHEMBL524374

CC(NCC(=O)O)c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APAF1 O14727 1/20 0.62
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
CYP3A4 P08684 2/20 0.53
CASR P41180 2/20 0.53
CHRM2 P08172 1/20 0.53
HTR1A P08908 1/20 0.53
ADRA2A P08913 1/20 0.53
ADORA3 P0DMS8 1/20 0.53
CHRM1 P11229 1/20 0.53
SMPD1 P17405 1/20 0.53
DRD1 P21728 1/20 0.53
TBXA2R P21731 1/20 0.53
SLC6A2 P23975 1/20 0.53
SLC6A4 P31645 1/20 0.53
ADRA1A P35348 1/20 0.53
OPRM1 P35372 1/20 0.53
DRD3 P35462 1/20 0.53
HTR2B P41595 1/20 0.53
SLC6A3 Q01959 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL653596 1.00 APAF1 (0.62) APAF1MEN1KMT2ACYP3A4CASR
SCHEMBL157741 1.00 APAF1 (0.62) APAF1MEN1KMT2ACYP3A4CASR
Glycine SCHEMBL27727845 0.93 APAF1 (0.56) APAF1MEN1KMT2ACYP3A4CASR
SCHEMBL24433342 0.86 APAF1 (0.61) APAF1MEN1KMT2ACYP3A4CASR
SCHEMBL1049426 0.85 APAF1 (0.46) APAF1MEN1KMT2A
SCHEMBL1881712 0.85 APAF1 (0.59) APAF1MEN1KMT2ACYP3A4CASR
SCHEMBL1881711 0.85 APAF1 (0.59) APAF1MEN1KMT2ACYP3A4CASR
SCHEMBL6809830 0.83 APAF1 (0.57) APAF1MEN1KMT2ACYP3A4CASR
SCHEMBL2408159 0.83 APAF1 (0.57) APAF1MEN1KMT2ACYP3A4CASR
SCHEMBL2408156 0.83 APAF1 (0.57) APAF1MEN1KMT2ACYP3A4CASR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025038979-A1 COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND/OR TREATMENT OF AMYLOID B PEPTIDE PROTEINOPENIA IN ALZHEIMER'S AND OTHER DISEASES LVIS-Regain LP (US) 2025-02-20 WO claimed
US-20240360177-A1 PEPTIDES WITH ANTIMICROBIAL ACTIVITIES AIMMAX THERAPEUTICS, INC. 2024-10-31 US claimed
CN-117897394-A Peptides with antimicrobial activity 美商安满药物开发公司 2024-04-16 CN claimed
EP-3994238-B1 LUBRICATING COMPOSITIONS CONTAINING BASIC ASHLESS ADDITIVES LUBRIZOL CORP (US) 2024-03-13 EP claimed
US-11859148-B2 Basic ashless additives and lubricating compositions containing same THE LUBRIZOL CORPORATION (US) 2024-01-02 US claimed
EP-3328877-B1 PEPTOID THE UNIV OF DURHAM (GB) 2022-08-24 EP claimed
CN-114105811-A New etomidate impurity, preparation method and application thereof 北京四环制药有限公司 2022-03-01 CN claimed
US-10676509-B2 Surface-immobilized antimicrobial peptoids NORTHWESTERN UNIVERSITY (US) 2020-06-09 US claimed
US-20180201647-A1 Peptoid THE UNIVERSITY OF DURHAM (GB) 2018-07-19 US claimed
EP-0017850-B1 N,N-DISUBSTITUTED ETHYLGLYCINE ESTERS, THEIR PREPARATION AND USE, FUNGICIDES CONTAINING THEM AND THEIR PREPARATION BAYER AG (DE) 1982-12-08 EP claimed
EP-4731270-A1 COMBINATION THERAPY WITH PEPTIDE RECEPTOR RADIONUCLIDE AND DNA REPAIR INHIBITOR The Regents of The University of California (US) 2026-04-29 EP disclosed
US-20260083852-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR UNIV CALIFORNIA (US) 2026-03-26 US disclosed
US-12485182-B2 Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-12-02 US disclosed
WO-2025038979-A1 COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND/OR TREATMENT OF AMYLOID B PEPTIDE PROTEINOPENIA IN ALZHEIMER'S AND OTHER DISEASES LVIS-Regain LP (US) 2025-02-20 WO disclosed
WO-2025005781-A1 ANTIMICROBIAL PEPTOID COMPRISING N-TERMINAL METAL COMPLEX 광주과학기술원 2025-01-02 WO disclosed
EP-0489767-A1 CCK ANTAGONISTS. BIOMEASURE INC (US) 1992-06-17 EP disclosed
WO-1991019735-A1 LIBRARIES OF MODIFIED PEPTIDES WITH PROTEASE RESISTANCE BARTLETT PAUL A (US) 1991-12-26 WO disclosed
WO-1991002719-A2 CCK ANTAGONISTS BIOMEASURE, INC. (US) 1991-03-07 WO disclosed
EP-0017850-B1 N,N-DISUBSTITUTED ETHYLGLYCINE ESTERS, THEIR PREPARATION AND USE, FUNGICIDES CONTAINING THEM AND THEIR PREPARATION BAYER AG (DE) 1982-12-08 EP disclosed
EP-0017850-A1 N,N-disubstituted ethylglycine esters, their preparation and use, fungicides containing them and their preparation BAYER AG (DE) 1980-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180201647-A1 Peptoid ARG1, ARGLU1, QPCT APAF1 4395/4885MEN1 988/4885KMT2A 1117/4885
US-12485182-B2 Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair PDGFA, PDGFRB, TEK APAF1 1685/4885MEN1 4811/4885KMT2A 4334/4885
US-20260083852-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR PDGFA, DCLRE1A, PDGFRA APAF1 2410/4885MEN1 4697/4885KMT2A 2690/4885
US-20240360177-A1 PEPTIDES WITH ANTIMICROBIAL ACTIVITIES VIP, FPR2, FPR1 APAF1 298/4885MEN1 3021/4885KMT2A 4839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.